ALPMF (Astellas Pharma) Buildings And Improvements: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMF Astellas Pharma Inc ALPMF
76 GF Score
Price $15.60
GF Value $15.49
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Buildings And Improvements?

Astellas Pharma ALPMF -1.58% 76 Buildings And Improvements is $0 Mil as of Jun. 2026. GuruFocus rates ALPMF with a GF Score™ of 76/100 and a GF Value™ of $15.49 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Buildings And Improvements Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Astellas Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ALPMF
76GF Score
Astellas Pharma Inc ALPMF
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $0 Mil mean?
Astellas Pharma (ALPMF) has a Buildings And Improvements of $0 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Buildings And Improvements too high?
Astellas Pharma's current Buildings And Improvements is $0 Mil. Overall, Astellas Pharma has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Buildings And Improvements compare to LLY and JNJ?
Astellas Pharma's Buildings And Improvements of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Drug Manufacturers company?
A good Buildings And Improvements depends on the Drug Manufacturers industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Buildings And Improvements is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $15.49, compared to a current price of $15.60 — trading 0.7% above its estimated fair value. The current Buildings And Improvements is $0 Mil. Astellas Pharma's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Buildings And Improvements is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of $15.60 is trading 0.7% above its estimated GF Value™ of $15.49. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Buildings And Improvements: $0 Mil
  • GF Value™: $15.49 vs. price of $15.60 (0.7% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
76GF Score

Get the complete analysis for ALPMF

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60
Price
$15.49
GF Value